SEARCH:   Advanced

Blood, 15 October 2008, Vol. 112, No. 8, pp. 3130-3134. Prepublished online as a Blood First Edition Paper on July 29, 2008; DOI 10.1182/blood-2008-05-159632. This Article Full Text (PDF) All Versions of this Article: blood-2008-05-159632v1 112/8/3130    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sanz, M. A Articles by Lowenberg, B. Search for Related Content PubMed PubMed Citation Articles by Sanz, M. A Articles by Lowenberg, B. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 28, 2008 Accepted July 8, 2008 Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group Miguel A Sanz*, Pau Montesinos, Edo Vellenga, Consuelo Rayon, Javier de la Serna, Ricardo Parody, Juan M. Bergua, Angel Leon, Silvia Negri, Marcos Gonzalez, Concha Rivas, Jordi Esteve, Gustavo Milone, Jose D Gonzalez, Elena Amutio, Salut Brunet, J. Garcia-Larana, Dolors Colomer, Maria J Calasanz, Carmen Chillon, Eva Barragan, Pascual Bolufer, and Bob Lowenberg Hematology Service, Hospital Universitario La Fe, Valencia, Spain Department of Medicine of Universitat Autònoma de Barcelona, Hospital Universitario La Fe,, Valencia, Spain Hematology Department, UMCG, Groningen, Netherlands Hematology Service, Hospital Central de Asturias, Oviedo, Spain Hematology Service, Hospital Universitario 12 de Octubre, Madrid, Spain Hematology Service, H.U. Virgen del Rocio, Sevilla, Spain Hematology Service, Hospital San Pedro de Alcantara, Cáceres, Spain Hematology Service, Hospital General Jerez de la Frontera, Jerez de la Frontera, Spain Hematology Service, Hospital Carlos Haya, Málaga, Spain Hospital Universitario, Salamanca, Spain Hematology Service, Hospital General de Alicante, Alicante, Spain Hematology Service, Hospital Clinic, Barcelona, Spain Hematology Service, Fundaleu, Buenos Aires, Argentina Hematology Service, Hospital Universitario de Salamanca, Salamanca, Spain Hematology Service, Hospital de Cruces, Baracaldo, Spain Hematology Service, Hospital Sant Pau, Barcelona, Spain Hematology Service, Hospital Ramon y Cajal, Madrid, Spain Department of Genetics, Universidad de Navarra, Pamplona, Spain Hematology Department, University Hospital Erasmus, Rotterdam, Netherlands * Corresponding author; email: msanz{at}uv.es. A previous report of the PETHEMA Group showed that a risk-adapted strategy combining all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for induction and consolidation in newly diagnosed acute promyelocytic leukemia (APL) results in an improved outcome. Here we report the analysis of treatment outcome of a significantly enlarged series of patients that have now been followed up for a median of 65 months. From November 1999 to July 2005 (LPA99 trial), 560 patients received induction therapy with ATRA plus idarubicin (AIDA regimen). Patients achieving complete remission received 3 monthly courses of risk-adapted consolidation followed by maintenance with ATRA and low-dose methotrexate and mercaptopurine. The 5-year cumulative incidence of relapse, disease-free survival, and overall survival were 11%, 84%, and 82%, respectively. These results compare favorably with those obtained in the previous LPA96 study (P = 0.019; P = 0.04; P = 0.07). This updated analysis confirms the high antileukemic efficacy, low toxicity and high degree of compliance of a risk-adapted strategy combining ATRA and reinforced anthracycline monochemotherapy for consolidation therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Schnittger, W. Kern, C. Tschulik, T. Weiss, F. Dicker, B. Falini, C. Haferlach, and T. Haferlach Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML Blood, September 10, 2009; 114(11): 2220 - 2231. [Abstract] [Full Text] [PDF] P. Montesinos, J. Diaz-Mediavilla, G. Deben, V. Prates, M. Tormo, V. Rubio, I. Perez, I. Fernandez, M. Viguria, C. Rayon, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis Haematologica, September 1, 2009; 94(9): 1242 - 1249. [Abstract] [Full Text] [PDF] C. Kelaidi, S. Chevret, S. De Botton, E. Raffoux, A. Guerci, X. Thomas, A. Pigneux, T. Lamy, F. Rigal-Huguet, S. Meyer-Monard, et al. Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience J. Clin. Oncol., June 1, 2009; 27(16): 2668 - 2676. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020